AF and PCI in Practice

Program Goals

Antithrombotic Therapy for AF and PCI

WOEST Trial: Triple vs Dual Therapy

WOEST Trial: Omission of Aspirin Reduces Bleeding

WOEST Trial: Omission of Aspirin Reduces Thrombosis

2014 ACC/AHA/HRS Guidelines for AF

2014 European Consensus: Antithrombotic Management in AF Patients With ACS/PCI

AF + PCI: A North American Perspective -- 2016 Update

AF + PCI: A North American Perspective -- 2016 Update (cont)

Antithrombotic Therapy for AF and PCI

PPI Use Reduces GI Bleeding Risk

Bleeding Reduction Strategies

Which Antiplatelet Agent to Discontinue?

RE-DUAL PCI Study Design

RE-DUAL PCI Primary Endpoint: Time to First Bleeding Event

RE-DUAL PCI: Rates of TIMI Major Bleeding

RE-DUAL PCI: Rate of Intracranial Hemorrhage

RE-DUAL PCI: Time to Death or Thromboembolic Event, or Unplanned Revascularization

RE-DUAL PCI: Additional Individual Thromboembolic Endpoints

PIONEER AF-PCI Study Design

PIONEER AF-PCI: Primary Endpoint Results

PIONEER-AF PCI: Thrombotic Events

PIONEER-AF PCI: Major Adverse Cardiac Events

Clinical Practice Implications of Trial Data

New ESC Focused Update on DAPT in CAD

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)